Motixafortide acetate is a Synthetic Peptide owned by BioLineRx, and is involved in 19 clinical trials, of which 9 were completed, 8 are ongoing, and 2 are planned.

Motixafortide acts as a high-affinity antagonist for chemokine (C-X-C Motif) receptor 4 (CXCR4). CXCR4 is a chemokine receptor that is directly involved in tumor progression, angiogenesis (growth of new blood vessels in the tumor), metastasis (spread of the disease to other organs or organ parts) and cell survival. BL-8040 selectively binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor-1 (SDF-1 or CXCL12) to the CXCR4 receptor and subsequent receptor activation, which may result in decreased tumor cell proliferation and migration. In addition, inhibition of CXCR4 may induce mobilization of hematopoietic cells from the bone marrow into blood.

The revenue for Motixafortide acetate is expected to reach a total of $1.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Motixafortide acetate NPV Report.

Motixafortide acetate was originated by Hadasit Medical Research Services and Development and Kyoto University and is currently owned by BioLineRx.

Motixafortide acetate Overview

Motixafortide is under development for the treatment of hematological cancers including chronic myeloid leukemia, metastatic adenocarcinoma of the pancreas, non-Hodgkin's lymphoma, neuroblastoma, melanoma, thrombocytopenia, aplastic anemia (AA), gastric cancer, adenocarcinoma of gastric or gastroesophageal junction, hypoplastic myelodysplastic syndrome, metastatic pancreatic adenocarcinoma, small cell lung cancer, metastatic pancreatic ductal adenocarcinoma, multiple myeloma, sickle cell disease and acute respiratory distress syndrome (ARDS) secondary to COVID-19, acute myeloid leukemia and other respiratory viral infections. The drug candidate is administered through subcutaneous and intravenous route. BL-8040 is a short peptide. It acts by targeting chemokine (C-X-C Motif) receptor 4 (CXCR4). The company was developing relapsed/refractory acute myeloid leukemia (AML) and squamous non-small cell lung cancer (first and third-line therapy), hematopoietic stem cell transplantation.

BioLineRx Overview

BioLineRx is a clinical-stage biopharmaceutical company that focuses on the development of products related to cancer and immunology. Its pipeline product BL-8040 is for the treatment of acute myeloid leukemia (AML), and relapsed or refractory AML. The company’s other pipeline drug candidate AGI-134 is synthetic alpha-gal immunotherapy that finds application in the treatment of solid tumors. BioLineRx‘s only product BL-5010 is a novel medical device indicated for the non-surgical removal of skin lesions. BioLineRx is headquartered in Modi’in-Maccabim-Re’ut, Israel.

The operating loss of the company was US$24.8 million in FY2021, compared to an operating loss of US$22.9 million in FY2020. The net loss of the company was US$27.1 million in FY2021, compared to a net loss of US$30 million in FY2020.

Quick View – Motixafortide acetate

Report Segments
  • Innovator
Drug Name
  • Motixafortide acetate
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Hematological Disorders
  • Immunology
  • Infectious Disease
  • Oncology
Key Companies
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.